Key result
Transapical beating-heart septal myectomy achieves ~88% procedural success in symptomatic nonobstructive HCM.
Why the study?
Nonobstructive hypertrophic cardiomyopathy (nHCM) remains challenging to treat because of its heterogeneous pathophysiology, prompting evaluation of the safety and efficacy of transapical beating-heart septal myectomy in symptomatic patients.
Does transapical beating-heart septal myectomy achieve procedural success (improvements in NYHA class, KCCQ score, stroke volume, and diastolic function) in patients with symptomatic, drug-refractory nonobstructive hypertrophic cardiomyopathy?
Does transapical beating-heart septal myectomy achieve procedural success (improvements in NYHA class, KCCQ score, stroke volume, and diastolic function) in patients with symptomatic, drug-refractory nonobstructive hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Transapical beating-heart septal myectomy achieved an 87.6% procedural success rate at 6 to 12 months with significant improvements in symptoms, stroke volume, and diastolic function in patients with symptomatic, drug-refractory nonobstructive hypertrophic cardiomyopathy.
BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (nHCM), defined as hypertrophic cardiomyopathy without left ventricular outflow tract obstruction, remains challenging to treat because of its heterogeneous pathophysiology. This study evaluated the safety and efficacy of transapical beating-heart septal myectomy in patients with symptomatic nHCM. METHODS: Patients with symptomatic, drug-refractory nHCM were prospectively enrolled to undergo transapical beating-heart septal myectomy through a left minithoracotomy. Under real-time transesophageal echocardiographic guidance, septal myectomy was tailored to relieve systolic cavity obliteration and mid-to-apical ventricular obstruction and to enlarge the left ventricular cavity. The primary end point was procedural success at 6 to 12 months postoperatively, defined as fulfillment of all prespecified criteria compared with baseline: ≥1-class improvement in New York Heart Association functional class, ≥10-point increase in Kansas City Cardiomyopathy Questionnaire score, ≥10-mL increase in stroke volume, and normal or grade I diastolic function. RESULTS: Between January 2023 and January 2025, 97 consecutive eligible patients with nHCM underwent transapical beating-heart septal myectomy at Tongji Hospital. At postoperative 6 to 12 months, procedural success was achieved in 87.6%. Specifically, New York Heart Association functional class I increased from 0% at baseline to 93.8% at follow-up, the median Kansas City Cardiomyopathy Questionnaire score improved from 64 (interquartile range, 56–69) to 87 (interquartile range, 82–92; P <0.001), the stroke volume increased from 53.5 mL (interquartile range, 41.0–66.6 mL) to 70.8 mL (interquartile range, 61.3–82.3 mL; P <0.001), and normal or grade I diastolic function increased from 65.6% to 97.9%. Among patients who underwent paired cardiopulmonary exercise testing (n=58), peak oxygen uptake increased by 1.1±2.9 mL/kg/min ( P =0.008). In an exploratory, hypothesis-generating analysis of 12 patients with paired 1 3 N-ammonia positron emission tomography, coronary flow reserve increased from 1.8±0.3 to 2.0±0.4 ( P =0.034). Adverse events included mitral valve injury (n=1) and ventricular septal perforation (n=1), the latter resulting in 1 postoperative death. CONCLUSIONS: Transapical beating-heart septal myectomy was associated with favorable left ventricular geometric remodeling and meaningful improvements in symptoms, health status, and functional capacity in selected patients with symptomatic nHCM. Being a potential therapeutic option for a previously difficult-to-treat population, it warrants further evaluation in controlled, multicenter studies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05648825.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) studied Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) (n=97). Transapical beating-heart septal myectomy was evaluated on Procedural success at 6 to 12 months postoperatively (≥1-class NYHA improvement, ≥10-point KCCQ increase, ≥10-mL stroke volume increase, and normal or grade I diastolic function). Transapical beating-heart septal myectomy achieved procedural success in 87.6% of patients with symptomatic nonobstructive HCM at 6 to 12 months, improving quality of life score and stroke volume.
Synapse has enriched 10 related papers. Consider them for comparative context: